comparing cardiovascular and kidney outcomes with tirzepatide vs. glp-1 agonists Comparative effectiveness of versus receptor on cardiovascular–kidney–metabolic stage progression: a real-world cohort study The Role of Glucagon-Like Peptide-1
Description
However, several studies and metaanalyses [65, 66, 67, 68, 69, 70, 71] demonstrated no increased risk of pancreatitis with GLP1 RAs, including a metaanalysis with over 55 randomized controlled trials [65, 72]
What else you should know You might need to take semaglutide for life to manage your weight
The bottom line: Retatrutide is promising to be a great tool for help with weight loss, but its not the only path forward for many people today
The only difference is the approved use printed on the label
White-space opportunities extend to oral formulations and multi-indication positioning for cardio-renal protection
